Istanbul, Prof. Dr. Cemil Taşçıoğlu City Hospital, Turkey
Istanbul, Turkey (Türkiye)
Location status: Recruiting
Location contact
Büşra Aydın Erkılıç, MSc
CONTACT
Büşra Aydın Erkılıç, MSc
PRINCIPAL_INVESTIGATOR
NCT Number: NCT07489794
This study aims to investigate the relationship between urinary incontinence severity and surface electromyography (EMG) findings in women with multiple sclerosis. It will also examine the association of urinary incontinence with disability, quality of life, physical activity, and fatigue.
Interested in participating?
Request Info30 year–50 year
Female
Observational
Istanbul, Turkey (Türkiye)
Location status: Recruiting
Büşra Aydın Erkılıç, MSc
CONTACT
Büşra Aydın Erkılıç, MSc
PRINCIPAL_INVESTIGATOR
This study investigates the relationship between urinary incontinence (UI) severity and pelvic floor muscle activity in women with multiple sclerosis (MS). UI is common in MS and negatively affects quality of life, physical activity, and social participation. The study also explores how UI severity is associated with disability, fatigue, and overall quality of life.
Participants' demographic and clinical information, including age, disease duration, MS type, and disability level (measured by the Expanded Disability Status Scale, EDSS), will be recorded. Standardized questionnaires will assess urinary symptoms, their impact on daily life, physical activity, and fatigue. Pelvic floor muscle activity will be evaluated using surface electromyography (EMG) with biofeedback, conducted by trained physiotherapists.
The study will be conducted at the Pelvic Floor Health Center and is planned as a cross-sectional study. All assessments, including questionnaires and EMG measurements, are expected to take approximately 45 minutes per participant. Findings from this study aim to improve understanding of UI in women with MS and guide future interventions.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Diagnosis of multiple sclerosis (MS) according to the 2017 revised McDonald criteria.
Female patients aged 30-50 years (age range with higher prevalence of urinary incontinence in MS).
Experiencing urinary incontinence (UI) symptoms according to the International Continence Society (ICS) definition.
EDSS (Expanded Disability Status Scale) score below 6.5.
Patients with no communication difficulties. -
Exclusion criteria
MS patients who do not provide consent to participate in the study.
MS patients who have had a medication change within the last 6 months.
Pregnant MS patients.
History of vaginal or cesarean delivery within the last 6 months.
Pelvic organ prolapse.
Urinary tract infection
-
Time frame: baseline
Evaluated using biofeedback-assisted surface EMG. Metrics recorded include mean EMG activity during contraction and rest phases, standard deviation of EMG activity, peak and minimum EMG values, contraction onset, and relaxation times
Time frame: baseline
Assesses severity and impact of urinary incontinence
Time frame: baseline
Evaluates the effect of urinary incontinence on quality of life
Time frame: baseline
Assesses participants' physical activity levels
Time frame: baseline
Measures severity of fatigue experienced by participants
Contact information is provided by the study sponsor or research team.
Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization
Other
FACTORS ASSOCIATED WITH URINARY INCONTINENCE AND EVALUATION OF PELVIC FLOOR MUSCLE ACTIVITY IN PATIENTS WITH MULTIPLE SCLEROSIS: CROSS-SECTIONAL STUDY
Acronym: MS-UI-PFM
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07236684
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Istanbul, Turkey (Türkiye)
View Trial DetailsNCT06505421
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
New York, United States
View Trial DetailsNCT07118514
Anxiety Disorders, Autoimmune Diseases
Maringá, Paraná, Brazil
View Trial DetailsNCT05826431
Activity, Motor, Autoimmune Diseases
Seattle, Washington, United States
View Trial Details